z-logo
open-access-imgOpen Access
ACE2 Antagonizes VEGFa to Reduce Vascular Permeability During Acute Lung Injury
Author(s) -
Xiuchong Yu,
Qiang Lin,
Qian Xiong,
Zheng Ruan,
Jianhua Zhou,
Zhixiong Lin,
Yijiang Su,
Jian Zheng,
Zhenwei Liu
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000443056
Subject(s) - vascular endothelial growth factor a , vascular permeability , lung , angiotensin converting enzyme 2 , bleomycin , vascular endothelial growth factor , medicine , pharmacology , chemistry , cancer research , vegf receptors , chemotherapy , covid-19 , disease , infectious disease (medical specialty)
Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI), through antagonizing hydrolyzing angiotensin II (AngII) and the ALI-induced apoptosis of pulmonary endothelial cells. Nevertheless, the effects of ACE2 on vessel permeability and its relationship with vascular endothelial growth factor a (VEGFa) remain ill-defined. In the current study, we examined the relationship between ACE2 and VEGFa in ALI model in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here